This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Vivotif

PaxVax Corporation

Drug Names(s): Vivotif, Typhoid Vaccine Live Oral Ty21a, Typhoral

Description: Vivotif (Typhoid Vaccine Live Oral Ty21a) is a live attenuated vaccine for oral administration only. The vaccine contains the attenuated strain Salmonella typhi Ty21a.

Deal Structure: Crucell & Berna
In February 2006, Crucell acquired Berna Biotech, which develops, produces and markets vaccines for private and public markets world-wide.

Johnson & Johnson and Crucell
In October 2010, Johnson & Johnson and Crucell announced an agreement whereby Johnson & Johnson, through an affiliate, would acquire all outstanding equity of Crucell that it does not already own for approximately Euro 1.75 billion in a recommended cash tender offer. The acquisition was declared unconditional and completed in February 2011.

PaxVax and Crucell
In July 2014, PaxVax announced that it has acquired Vivotif from Crucell Switzerland AG, as well as its manufacturing facility in Thrishaus, near Bern, Switzerland. Additionally, PaxVax is acquiring marketing, sales and distribution capabilities in select markets including the United States, and certain other assets related to travel vaccines such as hepatitis A. Financial terms of the transaction were...See full deal structure in Biomedtracker


Vivotif News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug